Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Organisation › Details

PX’Therapeutics S.A.

PX'Therapeutics is a biopharmaceutical contract research and manufacturing organisation specialising in the development of therapeutic antibodies and recombinant proteins from early research stage up to clinical grade GMP manufacturing. With more than 160 clients in Europe, North America and Japan, PX'Therapeutics has acquired an extensive knowledge in the production of valuable therapeutic candidates. *


Period Start 2008-09-29 renamed
  Group Aguettant (Group)
Product Industry contract manufacturing (biologicals)
Persons Person Rougemond, Eric (Aguettant 201302– CEO)
  Person 2 Rousselle, Tristan (Protein’eXpert 200011–201306 CEO + Co-Founder LEFT 6/13 before Genome Express)
Region Region Grenoble
  Country France
  Street 7 Parvis Louis Néel
  City 38040 Grenoble cedex 9
  Tel +33-438-023-650
    Address record changed: 2019-02-20
Basic data Employees B: 11 to 50 (2012-10-01)
  Currency EUR
  Annual sales 8,500,000 (revenues (2011) 2011-12-31)
    * Document for �About Section�: PX’Therapeutics S.A.. (9/6/11). "Press Release: PX’Therapeutics Licenses Ribovax’s SEBVI Technology for the Development and Manufacturing of Fully Human Monoclonal Antibodies".
Record changed: 2019-02-20


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Aguettant (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture [LSUS] – The Business Web Portal 600x60px

» top